Literature DB >> 1401204

Increased interleukin 6 concentrations in the absence and presence of HIV-1 infection in haemophilia.

R Madhok1, A Cruickshank, A J Gracie, A Shenkin, G D Lowe.   

Abstract

AIMS: To measure IL-6 concentrations in asymptomatic HIV-1 antibody positive and negative haemophilic patients and to correlate these with IgG concentrations and CD4 positive cell numbers.
METHODS: IL-6 concentrations were measured by bioassay in stored serum from a prospective cohort of haemophilic patients in whom immunoglobulins and T cell subsets had been determined. Values of IL-6 and immunoglobulins were also correlated with severity of liver disease.
RESULTS: IL-6 concentrations were raised in haemophilic patients independent of HIV-1 antibody status. In HIV-1 antibody positive patients there was no correlation between IL-6 concentrations and CD4 positive cell numbers, but there was a correlation with IgG (r = 0.4; p = 0.05). In HIV-1 antibody negative patients there were no significant correlations.
CONCLUSIONS: Haemophilic patients have increased IL-6 concentrations; in HIV-1 positive patients this is independent of the decline in CD4 cell count. The raised concentrations do not correlate with the clinical severity of liver disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401204      PMCID: PMC495100          DOI: 10.1136/jcp.45.9.766

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  17 in total

1.  Detection by in situ hybridization and phenotypic characterization of cells expressing IL-6 mRNA in human stimulated blood.

Authors:  K Kato; T Yokoi; N Takano; H Kanegane; A Yachie; T Miyawaki; N Taniguchi
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

2.  Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells.

Authors:  F R Jirik; T J Podor; T Hirano; T Kishimoto; D J Loskutoff; D A Carson; M Lotz
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

3.  Abnormalities of in vitro immunoglobulin production in apparently healthy haemophiliacs: relationship with alterations of T cell subsets and with HTLV-III seropositivity.

Authors:  R Biagiotti; M G Giudizi; F Almerigogna; M Mazzetti; A Alessi; G F Del Prete; D Rafanelli; M Fiorilli; M Morfini; S Romagnani
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

4.  Stimulation of murine hemopoietic colony formation by human IL-6.

Authors:  G G Wong; J S Witek-Giannotti; P A Temple; R Kriz; C Ferenz; R M Hewick; S C Clark; K Ikebuchi; M Ogawa
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  B cell dysfunction in haemophilia in the absence and presence of HIV-1 infection.

Authors:  R Madhok; J A Gracie; C D Forbes; G D Lowe
Journal:  Thromb Haemost       Date:  1991-01-23       Impact factor: 5.249

7.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production.

Authors:  C M Snapper; W E Paul
Journal:  Science       Date:  1987-05-22       Impact factor: 47.728

8.  Defect in B cell function in HTLV III/LAV positive hemophilia patients.

Authors:  E J Sjamsoedin-Visser; C J Heijnen; B J Zegers; J W Stoop
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

9.  Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection.

Authors:  M V Ragni; F L Ruben; A Winkelstein; J A Spero; F A Bontempo; J H Lewis
Journal:  J Lab Clin Med       Date:  1987-05

10.  Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas.

Authors:  J Van Snick; A Vink; S Cayphas; C Uyttenhove
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.